Views
11 months ago

Principles of pharmacology The Pathophysiologic basis of drug therapy 4e

Principles of pharmacology The Pathophysiologic basis of drug therapy

  • Page 3: P R I N C I P L E S o f P H A R M A
  • Page 6 and 7: Acquisitions Editor: Matthew Hauber
  • Page 9 and 10: Contents Pre face .................
  • Page 11: Preface The editors are grate ul or
  • Page 15: Acknowledgments The editors are gra
  • Page 18 and 19: xvi Contributors Janet Chou, MD Ins
  • Page 20 and 21: xviii Contributors Elizabeth Mayne,
  • Page 23 and 24: I Fundamental Principles of Pharmac
  • Page 25 and 26: Chapter 1 Drug-Receptor Interaction
  • Page 27 and 28: Chapter 1 Drug-Receptor Interaction
  • Page 29 and 30: Chapter 1 Drug-Receptor Interaction
  • Page 31 and 32: Chapter 1 Drug-Receptor Interaction
  • Page 33 and 34: Chapter 1 Drug-Receptor Interaction
  • Page 35 and 36: Chapter 1 Drug-Receptor Interaction
  • Page 37 and 38: Chapter 1 Drug-Receptor Interaction
  • Page 39 and 40: Agonist C Competitive antagonist 2
  • Page 41 and 42: Chapter 2 Pharmacodynamics 19 A Lin
  • Page 43 and 44: Chapter 2 Pharmacodynamics 21 Anta
  • Page 45 and 46: % Contraction % Analgesia Chapter 2
  • Page 47 and 48: Chapter 2 Pharmacodynamics 25 A Dru
  • Page 49 and 50: Free Bound Free Bo 3 Pharmacokineti
  • Page 51 and 52: [1,000] HA [1] A - + H + Stomach pH
  • Page 53 and 54:

    Chapter 3 Pharmacokinetics 31 o car

  • Page 55 and 56:

    Chapter 3 Pharmacokinetics 33 prima

  • Page 57 and 58:

    concentration Plasma drug concentra

  • Page 59 and 60:

    Chapter 3 Pharmacokinetics 37 drug

  • Page 61 and 62:

    Plasma drug concentration Plasma dr

  • Page 63 and 64:

    Plasma drug concentration Chapter 3

  • Page 65 and 66:

    1 H 2 O P450 -Fe Fe 3+ R- 4 O 2 - R

  • Page 67 and 68:

    Chapter 4 Drug Metabolism 45 TABLE

  • Page 69 and 70:

    Chapter 4 Drug Metabolism 47 Oxidat

  • Page 71 and 72:

    Chapter 4 Drug Metabolism 49 OH D D

  • Page 73 and 74:

    Chapter 4 Drug Metabolism 51 TABLE

  • Page 75 and 76:

    Chapter 4 Drug Metabolism 53 metabo

  • Page 77 and 78:

    Chapter 4 Drug Metabolism 55 Kirchh

  • Page 79 and 80:

    Chapter 5 Drug Transporters 57 Mr.

  • Page 81 and 82:

    Chapter 5 Drug Transporters 59 comp

  • Page 83 and 84:

    Chapter 5 Drug Transporters 61 TRAN

  • Page 85 and 86:

    Chapter 5 Drug Transporters 63 TABL

  • Page 87 and 88:

    Chapter 5 Drug Transporters 65 TABL

  • Page 89 and 90:

    Chapter 5 Drug Transporters 67 been

  • Page 91 and 92:

    Chapter 5 Drug Transporters 69 BOX

  • Page 93 and 94:

    Chapter 6 Drug Toxicity 71 Ms. G is

  • Page 95 and 96:

    Chapter 6 Drug Toxicity 73 A Hapten

  • Page 97 and 98:

    Chapter 6 Drug Toxicity 75 grepaf o

  • Page 99 and 100:

    Chapter 6 Drug Toxicity 77 A Drug H

  • Page 101 and 102:

    Chapter 6 Drug Toxicity 79 dermis,

  • Page 103 and 104:

    Chapter 6 Drug Toxicity 81 responsi

  • Page 105 and 106:

    Chapter 6 Drug Toxicity 83 BOX 6-1

  • Page 107 and 108:

    Chapter 6 Drug Toxicity 85 TABLE 6-

  • Page 109 and 110:

    %) Tamo xifen (TAM) OH 4-hydroxyTAM

  • Page 111 and 112:

    Chapter 7 Pharmacogenomics 89 TABLE

  • Page 113 and 114:

    Relapse-free survival (%) Disease-f

  • Page 115 and 116:

    Chapter 7 Pharmacogenomics 93 Precu

  • Page 117 and 118:

    Chapter 7 Pharmacogenomics 95 knowl

  • Page 119 and 120:

    IIA Fundamental Principles of Neuro

  • Page 121 and 122:

    Chapter 8 Principles o Cellular Exc

  • Page 123 and 124:

    Chapter 8 Principles o Cellular Exc

  • Page 125 and 126:

    Voltage (mV) Voltage (mV) Voltage (

  • Page 127 and 128:

    Voltage Conductance Chapter 8 Princ

  • Page 129 and 130:

    Chapter 8 Principles of Cellular Ex

  • Page 131 and 132:

    Chapter 8 Principles of Cellular Ex

  • Page 133 and 134:

    Chapter 9 Principles o Nervous Syst

  • Page 135 and 136:

    Chapter 9 Principles of Nervous Sys

  • Page 137 and 138:

    Chapter 9 Principles o Nervous Syst

  • Page 139 and 140:

    Chapter 9 Principles of Nervous Sys

  • Page 141 and 142:

    Chapter 9 Principles of Nervous Sys

  • Page 143 and 144:

    Chapter 9 Principles of Nervous Sys

  • Page 145 and 146:

    Chapter 9 Principles of Nervous Sys

  • Page 147 and 148:

    Chapter 9 Principles of Nervous Sys

  • Page 149 and 150:

    Na + Cholinergic neuron Choline AcC

  • Page 151 and 152:

    Chapter 10 Cholinergic Pharmacology

  • Page 153 and 154:

    Chapter 10 Cholinergic Pharmacology

  • Page 155 and 156:

    Chapter 10 Cholinergic Pharmacology

  • Page 157 and 158:

    Me mbra ne pote ntia l (mV) Voltage

  • Page 159 and 160:

    Chapter 10 Cholinergic Pharmacology

  • Page 161 and 162:

    Chapter 10 Cholinergic Pharmacology

  • Page 163 and 164:

    Chapter 10 Cholinergic Pharmacology

  • Page 165 and 166:

    Chapter 10 Cholinergic Pharmacology

  • Page 167 and 168:

    DRUG SUMMARY TABLE: CHAPTER 10 Chol

  • Page 169 and 170:

    o choice or paralysis during intuba

  • Page 171 and 172:

    in the circulation, thus accelerati

  • Page 173 and 174:

    Chapter 11 Adrenergic Pharmacology

  • Page 175 and 176:

    Chapter 11 Adrenergic Pharmacology

  • Page 177 and 178:

    Chapter 11 Adrenergic Pharmacology

  • Page 179 and 180:

    Chapter 11 Adrenergic Pharmacology

  • Page 181 and 182:

    Chapter 11 Adrenergic Pharmacology

  • Page 183 and 184:

    Chapter 11 Adrenergic Pharmacology

  • Page 185 and 186:

    See Drug Summary Table: Chapter 15

  • Page 187 and 188:

    organs or prostate gland Concurrent

  • Page 189 and 190:

    Epineurium Perin ineu rium En doneu

  • Page 191 and 192:

    Chapter 12 Local Anesthetic Pharmac

  • Page 193 and 194:

    Chapter 12 Local Anesthetic Pharmac

  • Page 195 and 196:

    1 2 3 Needle injecting LA Epineuriu

  • Page 197 and 198:

    Chapter 12 Local Anesthetic Pharmac

  • Page 199 and 200:

    Chapter 12 Local Anesthetic Pharmac

  • Page 201 and 202:

    Chapter 12 Local Anesthetic Pharmac

  • Page 203 and 204:

    DRUG SUMMARY TABLE: CHAPTER 12 Loca

  • Page 205 and 206:

    IIC Principles of Central Nervous S

  • Page 207 and 208:

    Extracellular Intra cellula r Extra

  • Page 209 and 210:

    - current Cl Chapter 13 Pharmacolog

  • Page 211 and 212:

    Chapter 13 Pharmacology o GABAergic

  • Page 213 and 214:

    - current (% maximum) Cl Chapter 13

  • Page 215 and 216:

    Chapter 13 Pharmacology o GABAergic

  • Page 217 and 218:

    Chapter 13 Pharmacology of GABAergi

  • Page 219 and 220:

    Chapter 13 Pharmacology o GABAergic

  • Page 221 and 222:

    Chapter 13 Pharmacology of GABAergi

  • Page 223 and 224:

    Chapter 13 Pharmacology of GABAergi

  • Page 225 and 226:

    o age Zolpidem but binds is not to

  • Page 227 and 228:

    voltage-gated sodium channels (ther

  • Page 229 and 230:

    Chapter 14 Pharmacology of Dopamine

  • Page 231 and 232:

    Chapter 14 Pharmacology of Dopamine

  • Page 233 and 234:

    Chapter 14 Pharmacology o Dopaminer

  • Page 235 and 236:

    Chapter 14 Pharmacology of Dopamine

  • Page 237 and 238:

    Chapter 14 Pharmacology of Dopamine

  • Page 239 and 240:

    Chapter 14 Pharmacology of Dopamine

  • Page 241 and 242:

    Chapter 14 Pharmacology o Dopaminer

  • Page 243 and 244:

    Chapter 14 Pharmacology of Dopamine

  • Page 245 and 246:

    function when used alone and can au

  • Page 247 and 248:

    ormulation is use ul or treating po

  • Page 249 and 250:

    NE MAOI NE NE DOPGAL 15 Pharmacolog

  • Page 251 and 252:

    Chapter 15 Pharmacology o Serotoner

  • Page 253 and 254:

    Chapter 15 Pharmacology o Serotoner

  • Page 255 and 256:

    Chapter 15 Pharmacology of Serotone

  • Page 257 and 258:

    Chapter 15 Pharmacology o Serotoner

  • Page 259 and 260:

    Chapter 15 Pharmacology of Serotone

  • Page 261 and 262:

    Chapter 15 Pharmacology of Serotone

  • Page 263 and 264:

    Chapter 15 Pharmacology of Serotone

  • Page 265 and 266:

    eversible inhibitors o monoamine ox

  • Page 267 and 268:

    venla axine. longer hal -li e than

  • Page 269 and 270:

    Hypersensitivity Ergot agent or ser

  • Page 271 and 272:

    + + 1 Loss of inhi hibi bit tory su

  • Page 273 and 274:

    Me mbra ne pote ntia l (mV) Chapter

  • Page 275 and 276:

    Chapter 16 Pharmacology o Abnormal

  • Page 277 and 278:

    50 mV Chapter 16 Pharmacology of Ab

  • Page 279 and 280:

    + + Chapter 16 Pharmacology o Abnor

  • Page 281 and 282:

    Chapter 16 Pharmacology of Abnormal

  • Page 283 and 284:

    DRUG SUMMARY TABLE: CHAPTER 16 Phar

  • Page 285 and 286:

    Insomnia seizures some cases. enzym

  • Page 287 and 288:

    Alveolar partial p ress e ure (A tm

  • Page 289 and 290:

    Recovery Deepening from anesthesia

  • Page 291 and 292:

    Chapter 17 General Anesthetic Pharm

  • Page 293 and 294:

    Chapter 17 General Anesthetic Pharm

  • Page 295 and 296:

    Chapter 17 General Anesthetic Pharm

  • Page 297 and 298:

    Chapter 17 General Anesthetic Pharm

  • Page 299 and 300:

    P P I alv Chapter 17 General Anesth

  • Page 301 and 302:

    P P E E 0 Chapter 17 General Anesth

  • Page 303 and 304:

    Chapter 17 General Anesthetic Pharm

  • Page 305 and 306:

    Chapter 17 General Anesthetic Pharm

  • Page 307 and 308:

    Etomidate Induction Maintenance ane

  • Page 309 and 310:

    Appendix B Equations GAS CONCENTRAT

  • Page 311 and 312:

    Chapter 18 Pharmacology o Analgesia

  • Page 313 and 314:

    Chapter 18 Pharmacology of Analgesi

  • Page 315 and 316:

    Chapter 18 Pharmacology of Analgesi

  • Page 317 and 318:

    Chapter 18 Pharmacology of Analgesi

  • Page 319 and 320:

    Chapter 18 Pharmacology o Analgesia

  • Page 321 and 322:

    Chapter 18 Pharmacology of Analgesi

  • Page 323 and 324:

    Chapter 18 Pharmacology of Analgesi

  • Page 325 and 326:

    Chapter 18 Pharmacology o Analgesia

  • Page 327 and 328:

    ioavailable via several routes. to

  • Page 329 and 330:

    Severe hypertension Minimal Wider p

  • Page 331 and 332:

    Chapter 19 Pharmacology of Drugs of

  • Page 333 and 334:

    Chapter 19 Pharmacology o Drugs o A

  • Page 335 and 336:

    Chapter 19 Pharmacology o Drugs o A

  • Page 337 and 338:

    Chapter 19 Pharmacology of Drugs of

  • Page 339 and 340:

    Chapter 19 Pharmacology o Drugs o A

  • Page 341 and 342:

    Chapter 19 Pharmacology of Drugs of

  • Page 343 and 344:

    % % Maximal Maximal transduction bi

  • Page 345 and 346:

    Chapter 19 Pharmacology of Drugs of

  • Page 347 and 348:

    Chapter 19 Pharmacology of Drugs of

  • Page 349 and 350:

    Chapter 19 Pharmacology of Drugs of

  • Page 351 and 352:

    Chapter 19 Pharmacology of Drugs of

  • Page 353 and 354:

    Chapter 19 Pharmacology of Drugs of

  • Page 355 and 356:

    ull opioid agonists. overdose. The

  • Page 357 and 358:

    III Principles of Cardiovascular Ph

  • Page 359 and 360:

    Chapter 20 Pharmacology of Choleste

  • Page 361 and 362:

    Chapter 20 Pharmacology o Cholester

  • Page 363 and 364:

    Chapter 20 Pharmacology o Cholester

  • Page 365 and 366:

    Chapter 20 Pharmacology o Cholester

  • Page 367 and 368:

    Chapter 20 Pharmacology o Cholester

  • Page 369 and 370:

    Chapter 20 Pharmacology of Choleste

  • Page 371 and 372:

    Chapter 20 Pharmacology of Choleste

  • Page 373 and 374:

    Chapter 20 Pharmacology of Choleste

  • Page 375 and 376:

    Chapter 20 Pharmacology o Cholester

  • Page 377 and 378:

    Chapter 20 Pharmacology of Choleste

  • Page 379 and 380:

    hepatic cholesterol synthesis. ente

  • Page 381 and 382:

    Chapter 21 Pharmacology of Volume R

  • Page 383 and 384:

    Chapter 21 Pharmacology o Volume Re

  • Page 385 and 386:

    Chapter 21 Pharmacology o Volume Re

  • Page 387 and 388:

    Chapter 21 Pharmacology o Volume Re

  • Page 389 and 390:

    Chapter 21 Pharmacology o Volume Re

  • Page 391 and 392:

    Chapter 21 Pharmacology o Volume Re

  • Page 393 and 394:

    Chapter 21 Pharmacology o Volume Re

  • Page 395 and 396:

    Chapter 21 Pharmacology of Volume R

  • Page 397 and 398:

    Chapter 21 Pharmacology of Volume R

  • Page 399 and 400:

    Chapter 21 Pharmacology of Volume R

  • Page 401 and 402:

    Chapter 21 Pharmacology of Volume R

  • Page 403 and 404:

    ANGIOTENSIN Mechanism—Antagonize

  • Page 405 and 406:

    ethacrynic acid has a di erent chem

  • Page 407 and 408:

    PLC Sarcopla smic re ticu culum G q

  • Page 409 and 410:

    Chapter 22 Pharmacology o Vascular

  • Page 411 and 412:

    Chapter 22 Pharmacology of Vascular

  • Page 413 and 414:

    Chapter 22 Pharmacology o Vascular

  • Page 415 and 416:

    Chapter 22 Pharmacology o Vascular

  • Page 417 and 418:

    Chapter 22 Pharmacology of Vascular

  • Page 419 and 420:

    Chapter 22 Pharmacology of Vascular

  • Page 421 and 422:

    diuretic. or dissecting aortic aneu

  • Page 423 and 424:

    PROSTACYCLIN Mechanism—Stimulate

  • Page 425 and 426:

    Low mole cula r weight (LMW) hepari

  • Page 427 and 428:

    Chapter 23 Pharmacology o Hemostasi

  • Page 429 and 430:

    Chapter 23 Pharmacology o Hemostasi

  • Page 431 and 432:

    Chapter 23 Pharmacology o Hemostasi

  • Page 433 and 434:

    Chapter 23 Pharmacology of Hemostas

  • Page 435 and 436:

    Chapter 23 Pharmacology o Hemostasi

  • Page 437 and 438:

    Chapter 23 Pharmacology o Hemostasi

  • Page 439 and 440:

    Chapter 23 Pharmacology of Hemostas

  • Page 441 and 442:

    Chapter 23 Pharmacology of Hemostas

  • Page 443 and 444:

    Chapter 23 Pharmacology o Hemostasi

  • Page 445 and 446:

    Chapter 23 Pharmacology of Hemostas

  • Page 447 and 448:

    Chapter 23 Pharmacology of Hemostas

  • Page 449 and 450:

    ticlopidine; signif cantly less mye

  • Page 451 and 452:

    thrombocytopenia in patients receiv

  • Page 453 and 454:

    can elicit antigenic responses in h

  • Page 455 and 456:

    A Normal conduction potentia l a No

  • Page 457 and 458:

    Repolarize Repolarize Depolarize De

  • Page 459 and 460:

    Chapter 24 Pharmacology o Cardiac R

  • Page 461 and 462:

    Me mbra ne pote ntia l (mV) Me mbra

  • Page 463 and 464:

    Chapter 24 Pharmacology o Cardiac R

  • Page 465 and 466:

    Me mbra ne pote ntia l (mV) Chapter

  • Page 467 and 468:

    Me mbra ne pote ntia l (mV) Me mbra

  • Page 469 and 470:

    Me mbra ne pote ntia l (mV) Chapter

  • Page 471 and 472:

    DRUG SUMMARY TABLE: CHAPTER 24 Phar

  • Page 473 and 474:

    CLASS Mechanism—Antagonize II ANT

  • Page 475 and 476:

    atrial utter disease Do not use ade

  • Page 477 and 478:

    Chapter 25 Pharmacology of Cardiac

  • Page 479 and 480:

    Chapter 25 Pharmacology o Cardiac C

  • Page 481 and 482:

    Chapter 25 Pharmacology o Cardiac C

  • Page 483 and 484:

    Chapter 25 Pharmacology o Cardiac C

  • Page 485 and 486:

    Chapter 25 Pharmacology of Cardiac

  • Page 487 and 488:

    Chapter 25 Pharmacology of Cardiac

  • Page 489 and 490:

    stenosis A racemic e predominantly

  • Page 491 and 492:

    Relative coronary blood flow 5 4 3

  • Page 493 and 494:

    Chapter 26 Integrative Cardiovascul

  • Page 495 and 496:

    Chapter 26 Integrative Cardiovascul

  • Page 497 and 498:

    Chapter 26 Integrative Cardiovascul

  • Page 499 and 500:

    Chapter 26 Integrative Cardiovascul

  • Page 501 and 502:

    Chapter 26 Integrative Cardiovascul

  • Page 503 and 504:

    Relative coronary blood flow Chapte

  • Page 505 and 506:

    Chapter 26 Integrative Cardiovascul

  • Page 507 and 508:

    Chapter 26 Integrative Cardiovascul

  • Page 509 and 510:

    Chapter 26 Integrative Cardiovascul

  • Page 511 and 512:

    LV P re s s ure (mm Hg) Chapter 26

  • Page 513 and 514:

    Cardiac output Cardiac output Chapt

  • Page 515 and 516:

    Chapter 26 Integrative Cardiovascul

  • Page 517 and 518:

    Chapter 26 Integrative Cardiovascul

  • Page 519 and 520:

    Estrogen SERM Cofa ctor Y strogen e

  • Page 521 and 522:

    Chapter 27 Pharmacology of the Hypo

  • Page 523 and 524:

    Chapter 27 Pharmacology of the Hypo

  • Page 525 and 526:

    Chapter 27 Pharmacology of the Hypo

  • Page 527 and 528:

    Chapter 27 Pharmacology of the Hypo

  • Page 529 and 530:

    Chapter 27 Pharmacology of the Hypo

  • Page 531 and 532:

    Chapter 27 Pharmacology of the Hypo

  • Page 533 and 534:

    gastrointestinal adverse e ects. an

  • Page 535 and 536:

    ailure, pituitary tumor, ovarian an

  • Page 537 and 538:

    Chapter 28 Pharmacology o the Thyro

  • Page 539 and 540:

    Chapter 28 Pharmacology o the Thyro

  • Page 541 and 542:

    Chapter 28 Pharmacology o the Thyro

  • Page 543 and 544:

    Chapter 28 Pharmacology of the Thyr

  • Page 545 and 546:

    DRUG SUMMARY TABLE: CHAPTER 28 Phar

  • Page 547 and 548:

    Chapter 29 Pharmacology o the Adren

  • Page 549 and 550:

    Chapter 29 Pharmacology of the Adre

  • Page 551 and 552:

    Chapter 29 Pharmacology o the Adren

  • Page 553 and 554:

    Chapter 29 Pharmacology of the Adre

  • Page 555 and 556:

    Chapter 29 Pharmacology o the Adren

  • Page 557 and 558:

    Chapter 29 Pharmacology of the Adre

  • Page 559 and 560:

    Chapter 29 Pharmacology o the Adren

  • Page 561 and 562:

    DRUG SUMMARY TABLE: CHAPTER 29 Phar

  • Page 563 and 564:

    30 Pharmacology of Reproduction Ehr

  • Page 565 and 566:

    Chapter 30 Pharmacology of Reproduc

  • Page 567 and 568:

    Male LH FSH LH-R FSH-R ABP Chapter

  • Page 569 and 570:

    Chapter 30 Pharmacology of Reproduc

  • Page 571 and 572:

    Chapter 30 Pharmacology o Reproduct

  • Page 573 and 574:

    Chapter 30 Pharmacology o Reproduct

  • Page 575 and 576:

    Chapter 30 Pharmacology of Reproduc

  • Page 577 and 578:

    Chapter 30 Pharmacology of Reproduc

  • Page 579 and 580:

    partial agonist in the endometrium

  • Page 581 and 582:

    or 3 years. growth o tissues derive

  • Page 583 and 584:

    tissues s Bloo d Glucose Me et ta b

  • Page 585 and 586:

    Chapter 31 Pharmacology of the Endo

  • Page 587 and 588:

    Chapter 31 Pharmacology o the Endoc

  • Page 589 and 590:

    Chapter 31 Pharmacology o the Endoc

  • Page 591 and 592:

    Chapter 31 Pharmacology o the Endoc

  • Page 593 and 594:

    Chapter 31 Pharmacology of the Endo

  • Page 595 and 596:

    Chapter 31 Pharmacology of the Endo

  • Page 597 and 598:

    DRUG SUMMARY TABLE: CHAPTER 31 Phar

  • Page 599 and 600:

    induce hypoglycemia. concerns about

  • Page 601 and 602:

    glucose administration is not possi

  • Page 603 and 604:

    Chapter 32 Pharmacology of Bone Min

  • Page 605 and 606:

    Chapter 32 Pharmacology o Bone Mine

  • Page 607 and 608:

    Chapter 32 Pharmacology of Bone Min

  • Page 609 and 610:

    Chapter 32 Pharmacology of Bone Min

  • Page 611 and 612:

    Bone mass Chapter 32 Pharmacology o

  • Page 613 and 614:

    Chapter 32 Pharmacology o Bone Mine

  • Page 615 and 616:

    Chapter 32 Pharmacology o Bone Mine

  • Page 617 and 618:

    Chapter 32 Pharmacology of Bone Min

  • Page 619 and 620:

    Chapter 32 Pharmacology of Bone Min

  • Page 621 and 622:

    DRUG SUMMARY TABLE: CHAPTER 32 Phar

  • Page 623 and 624:

    VITAMIN Mechanism—Increase Cholec

  • Page 625 and 626:

    Peptidoglycan cell w all Inhibi bit

  • Page 627 and 628:

    Chapter 33 Principles of Antimicrob

  • Page 629 and 630:

    Chapter 33 Principles o Antimicrobi

  • Page 631 and 632:

    Chapter 33 Principles o Antimicrobi

  • Page 633 and 634:

    Chapter 33 Principles o Antimicrobi

  • Page 635 and 636:

    Chapter 33 Principles o Antimicrobi

  • Page 637 and 638:

    Chapter 33 Principles of Antimicrob

  • Page 639 and 640:

    Chapter 33 Principles of Antimicrob

  • Page 641 and 642:

    Chapter 33 Principles of Antimicrob

  • Page 643 and 644:

    chemotherapy has been broadened by

  • Page 645 and 646:

    Chapter 34 Pharmacology o Bacterial

  • Page 647 and 648:

    Chapter 34 Pharmacology of Bacteria

  • Page 649 and 650:

    Chapter 34 Pharmacology of Bacteria

  • Page 651 and 652:

    Chapter 34 Pharmacology of Bacteria

  • Page 653 and 654:

    Chapter 34 Pharmacology of Bacteria

  • Page 655 and 656:

    Chapter 34 Pharmacology of Bacteria

  • Page 657 and 658:

    Chapter 34 Pharmacology o Bacterial

  • Page 659 and 660:

    DRUG SUMMARY TABLE: CHAPTER 34 Phar

  • Page 661 and 662:

    chromosomal mutations leading to al

  • Page 663 and 664:

    HO OHO O - O OOC OPO3 -2 NH O O AcH

  • Page 665 and 666:

    Chapter 35 Pharmacology of Bacteria

  • Page 667 and 668:

    Chapter 35 Pharmacology of Bacteria

  • Page 669 and 670:

    Chapter 35 Pharmacology o Bacterial

  • Page 671 and 672:

    Chapter 35 Pharmacology of Bacteria

  • Page 673 and 674:

    Chapter 35 Pharmacology of Bacteria

  • Page 675 and 676:

    Chapter 35 Pharmacology of Bacteria

  • Page 677 and 678:

    Chapter 35 Pharmacology of Bacteria

  • Page 679 and 680:

    potentiated by concomitant penicill

  • Page 681 and 682:

    less active against Gram-positive o

  • Page 683 and 684:

    36 Pharmacology of Fungal Infection

  • Page 685 and 686:

    Chapter 36 Pharmacology o Fungal In

  • Page 687 and 688:

    Chapter 36 Pharmacology of Fungal I

  • Page 689 and 690:

    Chapter 36 Pharmacology of Fungal I

  • Page 691 and 692:

    Chapter 36 Pharmacology of Fungal I

  • Page 693 and 694:

    or 7 days, whereas the 0.8% cream a

  • Page 695 and 696:

    ungistatic against Aspergillus unct

  • Page 697 and 698:

    Chapter 37 Pharmacology o Parasitic

  • Page 699 and 700:

    Chapter 37 Pharmacology o Parasitic

  • Page 701 and 702:

    Chapter 37 Pharmacology of Parasiti

  • Page 703 and 704:

    Chapter 37 Pharmacology of Parasiti

  • Page 705 and 706:

    Chapter 37 Pharmacology of Parasiti

  • Page 707 and 708:

    Chapter 37 Pharmacology of Parasiti

  • Page 709 and 710:

    Chapter 37 Pharmacology of Parasiti

  • Page 711 and 712:

    DRUG SUMMARY TABLE: CHAPTER 37 Phar

  • Page 713 and 714:

    eductase. o P. falciparum and P. vi

  • Page 715 and 716:

    om presynaptic terminals → hyperp

  • Page 717 and 718:

    Chapter 38 Pharmacology o Viral In

  • Page 719 and 720:

    Chapter 38 Pharmacology o Viral In

  • Page 721 and 722:

    Chapter 38 Pharmacology o Viral In

  • Page 723 and 724:

    Chapter 38 Pharmacology o Viral In

  • Page 725 and 726:

    A Native nucleosides NH 2 O NH 2 O

  • Page 727 and 728:

    Chapter 38 Pharmacology of Viral In

  • Page 729 and 730:

    Chapter 38 Pharmacology o Viral In

  • Page 731 and 732:

    Chapter 38 Pharmacology o Viral In

  • Page 733 and 734:

    Chapter 38 Pharmacology of Viral In

  • Page 735 and 736:

    Chapter 38 Pharmacology o Viral In

  • Page 737 and 738:

    Chapter 38 Pharmacology o Viral In

  • Page 739 and 740:

    Chapter 38 Pharmacology of Viral In

  • Page 741 and 742:

    penciclovir, the active orm o the d

  • Page 743 and 744:

    HIV drugs. once-a-day pill. are res

  • Page 745 and 746:

    39 C Pharmacology of Cancer: Genome

  • Page 747 and 748:

    Chapter 39 Pharmacology of Cancer:

  • Page 749 and 750:

    Chapter 39 Pharmacology of Cancer:

  • Page 751 and 752:

    Chapter 39 Pharmacology o Cancer: G

  • Page 753 and 754:

    Chapter 39 Pharmacology of Cancer:

  • Page 755 and 756:

    Chapter 39 Pharmacology o Cancer: G

  • Page 757 and 758:

    Chapter 39 Pharmacology of Cancer:

  • Page 759 and 760:

    Chapter 39 Pharmacology o Cancer: G

  • Page 761 and 762:

    Chapter 39 Pharmacology of Cancer:

  • Page 763 and 764:

    Chapter 39 Pharmacology o Cancer: G

  • Page 765 and 766:

    DRUG SUMMARY TABLE: CHAPTER 39 Phar

  • Page 767 and 768:

    causes hemorrhagic cystitis; this a

  • Page 769 and 770:

    exposure to cold temperatures. stom

  • Page 771 and 772:

    AGENTS THAT INHIBIT MICROTUBULE DEP

  • Page 773 and 774:

    Chapter 40 Pharmacology o Cancer: S

  • Page 775 and 776:

    Chapter 40 Pharmacology o Cancer: S

  • Page 777 and 778:

    Chapter 40 Pharmacology of Cancer:

  • Page 779 and 780:

    Chapter 40 Pharmacology of Cancer:

  • Page 781 and 782:

    Chapter 40 Pharmacology of Cancer:

  • Page 783 and 784:

    Chapter 40 Pharmacology of Cancer:

  • Page 785 and 786:

    Chapter 40 Pharmacology of Cancer:

  • Page 787 and 788:

    DRUG SUMMARY TABLE: CHAPTER 40 Phar

  • Page 789 and 790:

    polycythemia vera and essential thr

  • Page 791 and 792:

    asic f broblast growth actor (bFGF)

  • Page 793 and 794:

    Chapter 41 Principles o Combination

  • Page 795 and 796:

    MIC of Drug A Chapter 41 Principles

  • Page 797 and 798:

    Chapter 41 Principles of Combinatio

  • Page 799 and 800:

    Chapter 41 Principles o Combination

  • Page 801 and 802:

    Chapter 41 Principles of Combinatio

  • Page 803 and 804:

    Chapter 41 Principles of Combinatio

  • Page 805 and 806:

    A B No c osti mu la ti on With cos

  • Page 807 and 808:

    Chapter 42 Principles o Inf ammatio

  • Page 809 and 810:

    Chapter 42 Principles o Inf ammatio

  • Page 811 and 812:

    A B No costimulation With costimula

  • Page 813 and 814:

    Chapter 42 Principles o Inf ammatio

  • Page 815 and 816:

    Chapter 42 Principles o Inf ammatio

  • Page 817 and 818:

    Chapter 43 Pharmacology of Eicosano

  • Page 819 and 820:

    Chapter 43 Pharmacology o Eicosanoi

  • Page 821 and 822:

    Chapter 43 Pharmacology of Eicosano

  • Page 823 and 824:

    Chapter 43 Pharmacology o Eicosanoi

  • Page 825 and 826:

    Chapter 43 Pharmacology o Eicosanoi

  • Page 827 and 828:

    Chapter 43 Pharmacology of Eicosano

  • Page 829 and 830:

    Chapter 43 Pharmacology of Eicosano

  • Page 831 and 832:

    Chapter 43 Pharmacology o Eicosanoi

  • Page 833 and 834:

    Chapter 43 Pharmacology of Eicosano

  • Page 835 and 836:

    Chapter 43 Pharmacology o Eicosanoi

  • Page 837 and 838:

    DRUG SUMMARY TABLE: CHAPTER 43 Phar

  • Page 839 and 840:

    penile implant, Peyronie’s diseas

  • Page 841 and 842:

    α q/11 β γ α q/11 44 GD P GTP I

  • Page 843 and 844:

    Chapter 44 Histamine Pharmacology 8

  • Page 845 and 846:

    Chapter 44 Histamine Pharmacology 8

  • Page 847 and 848:

    Chapter 44 Histamine Pharmacology 8

  • Page 849 and 850:

    Chapter 44 Histamine Pharmacology 8

  • Page 851 and 852:

    used doses nondepressed in can pati

  • Page 853 and 854:

    Chapter 45 Pharmacology o Hematopoi

  • Page 855 and 856:

    Chapter 45 Pharmacology of Hematopo

  • Page 857 and 858:

    Chapter 45 Pharmacology o Hematopoi

  • Page 859 and 860:

    Chapter 45 Pharmacology of Hematopo

  • Page 861 and 862:

    Chapter 45 Pharmacology of Hematopo

  • Page 863 and 864:

    DRUG SUMMARY TABLE: CHAPTER 45 Phar

  • Page 865 and 866:

    actors that suppress tumor growth.

  • Page 867 and 868:

    Chapter 46 Pharmacology o Immunosup

  • Page 869 and 870:

    Chapter 46 Pharmacology o Immunosup

  • Page 871 and 872:

    Chapter 46 Pharmacology of Immunosu

  • Page 873 and 874:

    Chapter 46 Pharmacology of Immunosu

  • Page 875 and 876:

    Chapter 46 Pharmacology o Immunosup

  • Page 877 and 878:

    Chapter 46 Pharmacology of Immunosu

  • Page 879 and 880:

    Chapter 46 Pharmacology of Immunosu

  • Page 881 and 882:

    and the tacrolimus-FKBP complex inh

  • Page 883 and 884:

    ully human anti-CD20 antibodies. tu

  • Page 885 and 886:

    to be monitored for signs and sympt

  • Page 887 and 888:

    Chapter 47 Integrative Inf ammation

  • Page 889 and 890:

    Chapter 47 Integrative Inf ammation

  • Page 891 and 892:

    Chapter 47 Integrative Inf ammation

  • Page 893 and 894:

    Chapter 47 Integrative Inf ammation

  • Page 895 and 896:

    Chapter 47 Integrative Inf ammation

  • Page 897 and 898:

    DRUG SUMMARY TABLE: CHAPTER 47 Inte

  • Page 899 and 900:

    Nucleus Cytosol Prostaglandins As p

  • Page 901 and 902:

    Chapter 48 Integrative Inf ammation

  • Page 903 and 904:

    Airway smooth muscle contraction Ch

  • Page 905 and 906:

    Chapter 48 Integrative Inf ammation

  • Page 907 and 908:

    Chapter 48 Integrative Inf ammation

  • Page 909 and 910:

    Chapter 48 Integrative Inf ammation

  • Page 911 and 912:

    Chapter 48 Integrative Inf ammation

  • Page 913 and 914:

    Chapter 48 Integrative Inf ammation

  • Page 915 and 916:

    ood products (inhalation aerosol) T

  • Page 917 and 918:

    MSU crystals mo nosodium urate (MS

  • Page 919 and 920:

    Chapter 49 Integrative Inf ammation

  • Page 921 and 922:

    Chapter 49 Integrative Inf ammation

  • Page 923 and 924:

    Chapter 49 Integrative Inf ammation

  • Page 925 and 926:

    asolateral URAT1 anion exchanger in

  • Page 927 and 928:

    Carcin ogen exp xposure Excretion 5

  • Page 929 and 930:

    Chapter 50 Environmental Toxicology

  • Page 931 and 932:

    Chapter 50 Environmental Toxicology

  • Page 933 and 934:

    Chapter 50 Environmental Toxicology

  • Page 935 and 936:

    Chapter 50 Environmental Toxicology

  • Page 937 and 938:

    Chapter 50 Environmental Toxicology

  • Page 939 and 940:

    Chapter 50 Environmental Toxicology

  • Page 941 and 942:

    Linear flow synthesis A Flow reacto

  • Page 943 and 944:

    Chapter 51 Drug Discovery and Precl

  • Page 945 and 946:

    Chapter 51 Drug Discovery and Precl

  • Page 947 and 948:

    Chapter 51 Drug Discovery and Precl

  • Page 949 and 950:

    Chapter 51 Drug Discovery and Precl

  • Page 951 and 952:

    Chapter 51 Drug Discovery and Precl

  • Page 953 and 954:

    Chapter 51 Drug Discovery and Precl

  • Page 955 and 956:

    e ed i ed e il d A A A/BLA A fil D

  • Page 957 and 958:

    End of NDA/BLA phase 2 filed meetin

  • Page 959 and 960:

    Chapter 52 Clinical Drug Evaluation

  • Page 961 and 962:

    Chapter 52 Clinical Drug Evaluation

  • Page 963 and 964:

    Chapter 52 Clinical Drug Evaluation

  • Page 965 and 966:

    Chapter 52 Clinical Drug Evaluation

  • Page 967 and 968:

    Chapter 52 Clinical Drug Evaluation

  • Page 969 and 970:

    Chapter 53 Systematic Detection of

  • Page 971 and 972:

    Chapter 53 Systematic Detection o A

  • Page 973 and 974:

    Chapter 53 Systematic Detection o A

  • Page 975 and 976:

    Chapter 53 Systematic Detection of

  • Page 977 and 978:

    PROTEIN TRADE NAME FUNCTI TION EXAM

  • Page 979 and 980:

    Chapter 54 Protein Therapeutics 957

  • Page 981 and 982:

    Chapter 54 Protein Therapeutics 959

  • Page 983 and 984:

    Chapter 54 Protein Therapeutics 961

  • Page 985 and 986:

    Chapter 54 Protein Therapeutics 963

  • Page 987 and 988:

    Chapter 54 Protein Therapeutics 965

  • Page 989 and 990:

    Chapter 54 Protein Therapeutics 967

  • Page 991 and 992:

    Chapter 54 Protein Therapeutics 969

  • Page 993 and 994:

    Chapter 54 Protein Therapeutics 971

  • Page 995 and 996:

    Chapter 54 Protein Therapeutics 973

  • Page 997 and 998:

    Chapter 54 Protein Therapeutics 975

  • Page 999 and 1000:

    Chapter 54 Protein Therapeutics 977

  • Page 1001 and 1002:

    A B C Polymer capsule Polymer matri

  • Page 1003 and 1004:

    Chapter 55 Drug Delivery Modalities

  • Page 1005 and 1006:

    Chapter 55 Drug Delivery Modalities

  • Page 1007:

    Chapter 55 Drug Delivery Modalities

  • Page 1010 and 1011:

    988 Credit List Figure 14-9: Adapte

  • Page 1012 and 1013:

    990 Credit List Figure 43-2: Adapte

  • Page 1014 and 1015:

    992 Index Adrenal medulla, 111, 112

  • Page 1016 and 1017:

    994 Index Antineoplastic drugs (con

  • Page 1018 and 1019:

    996 Index Blood ow, abnormal, 412 B

  • Page 1020 and 1021:

    998 Index Cido ovir, 60 t , 65, 65

  • Page 1022 and 1023:

    1000 Index Directly Observed Therap

  • Page 1024 and 1025:

    1002 Index Ertapenem, 654, 659 t Er

  • Page 1026 and 1027:

    1004 Index Glutamate (continued) re

  • Page 1028 and 1029:

    1006 Index IL-1. See Interleukin-1

  • Page 1030 and 1031:

    1008 Index 5-Lipoxygenase-activatin

  • Page 1032 and 1033:

    1010 Index Myocytes anatomy o , 455

  • Page 1034 and 1035:

    1012 Index Pacemaker cells, 433 Pac

  • Page 1036 and 1037:

    1014 Index PP D t e st . See Purif

  • Page 1038 and 1039:

    1016 Index Scavenger receptors, 342

  • Page 1040 and 1041:

    1018 Index Tazobactam, 651, 653, 65

  • Page 1042:

    1020 Index Valdecoxib, 78, 295, 301

[+][PDF] TOP TREND Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy [NEWS]
A-Textbook-of-Clinical-Pharmacology-and-Therapeutics-5th-edition
General Principles of Pharmacology and Toxicology - Department of ...
A Textbook of Clinical Pharmacology and Therapeutics
Frontiers in Anti-Cancer Drug Discovery - Bentham Science
Principles of General and Autonomic Pharmacology
Principles of General and Autonomic Pharmacology
Principles of General and Autonomic Pharmacology
Carbon monoxide poisoning: pathophysiologic principles underlying ...
Flow cytometry for drug discovery, receptor pharmacology and high ...
N - Journal of Pharmacology and Experimental Therapeutics
Neuromuscular Junction - Pharmacology
The IUPHAR Compendium of Basic Principles For Pharmacological ...
TOC (PDF) - Journal of Pharmacology and Experimental ...
Neuromuscular Junction - Pharmacology Most drugs are effective ...
PHARMACOLOGY DEPARTMENT - Dubai Medical College - DMC
Title Page Title: Pharmacological Inhibition of Pleckstrin Homology ...
An examination of drug-drug interactions with raltegravir
An examination of drug-drug interactions with raltegravir
Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION